Therapeutic Effects of Dexmedetomidine on Colon Cancer Model Rats and Its Effects on RhoA/ROCK1 Signaling Pathway

ZHANG Zhezhe; QI Chao; ZHANG Xiaoling; ZHANG Mengtian; LIU Hongman

doi:10.14009/j.issn.1672-2124.2022.02.016

您当前的位置：

首页 >

文章列表页 >

Therapeutic Effects of Dexmedetomidine on Colon Cancer Model Rats and Its Effects on RhoA/ROCK1 Signaling Pathway

更新时间：2022-10-08

- Therapeutic Effects of Dexmedetomidine on Colon Cancer Model Rats and Its Effects on RhoA/ROCK1 Signaling Pathway
- Vol. 22, Issue 2, Pages: 188-192(2022)
- 作者机构：
  
  1. 廊坊市人民医院麻醉科
  2. 廊坊市人民医院消化科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.02.016
  CLC： R735.35;R614
- Published：2022，
扫描看全文
ZHANG Zhezhe, QI Chao, ZHANG Xiaoling, et al. Therapeutic Effects of Dexmedetomidine on Colon Cancer Model Rats and Its Effects on RhoA/ROCK1 Signaling Pathway. [J]. 22(2):188-192(2022)
DOI：

ZHANG Zhezhe, QI Chao, ZHANG Xiaoling, et al. Therapeutic Effects of Dexmedetomidine on Colon Cancer Model Rats and Its Effects on RhoA/ROCK1 Signaling Pathway. [J]. 22(2):188-192(2022) DOI： 10.14009/j.issn.1672-2124.2022.02.016.

摘要

目的：探讨右美托咪定对结肠癌模型大鼠的治疗作用及对Ras同源基因家族成员A(RhoA)/Rho相关卷曲螺旋蛋白激酶1(ROCK1)信号通路的影响。方法：通过1

2-二甲肼诱导建立结肠癌大鼠模型，将成模大鼠随机分为模型组，右美托咪定低(25μg/kg)、中(50μg/kg)和高(100μg/kg)剂量组，每组6只。另取6只未造模大鼠作为正常组。各组大鼠给予相应药物处理4周，观察大鼠的一般状况；检测大鼠血清肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)水平；解剖观察肿瘤的生长和分布情况；采用苏木精-伊红染色观察病理学变化；检测正常结肠组织和结肠癌组织中RhoA和ROCK1蛋白表达水平。结果：正常组大鼠体重随时间增长，结肠组织结构正常，无炎症细胞浸润；模型组大鼠体重增长缓慢，肛门红肿溃破、大便稀溏，结肠上可见突出肿瘤组织，结肠组织结构异常，炎症细胞浸润程度严重；右美托咪定低、中和高剂量组大鼠体重均高于模型组，肠壁糜烂出血情况有不同程度的减轻，结肠组织结构相比于模型组较为完整，炎症细胞浸润程度有所降低。相较于正常组，模型组大鼠血清TNF-α、IL-1β水平以及结肠癌组织RhoA和ROCK1蛋白表达水平显著升高，差异均有统计学意义(P<0.05);相较于模型组，右美托咪定低、中和高剂量组大鼠血清TNF-α、IL-1β水平以及结肠癌组织RhoA和ROCK1蛋白表达水平显著降低，差异均有统计学意义(P<0.05)。结论：右美托咪定对结肠癌大鼠具有一定的治疗作用，可能与其抑制RhoA/ROCK1通路有关。

Abstract

OBJECTIVE: To probe into the therapeutic effects of dexmedetomidine on colon cancer model rats and its effects on Ras homolog gene family member A（RhoA）/Rho-associated coiled-coil containing protein kinase 1（ROCK1） signal pathway. METHODS: The rat model of colon cancer was induced by 1

2-dimethylhydrazine

the model rats were randomly divided into the model group and low-dose（25 μg/kg）

medium-dose（50 μg/kg）

high-dose（100 μg/kg） dexmedetomidine group

with 6 rats in each group. Another 6 rats without model were taken as the normal group. Each group was treated with corresponding drugs for 4 weeks

the general condition of rats was observed. The serum tumor necrosis factor-α（TNF-α）

interleukin-1β（IL-1β） of rats was detected. The growth and distribution of tumors were observed

hematoxylin eosin（HE） staining was used to observe the pathological changes

the expressions of RhoA and ROCK1 proteins in normal colon tissues and colon cancer tissues were detected. RESULTS: The body weight of rats in the normal group increased steadily over time

and the colon tissue structure was normal without inflammatory cell infiltration. Rats in the model group had slow weight gain

red and swollen anus

loose stools

prominent tumor tissues on the colon

abnormal colonic tissue structure

and severe inflammatory cell infiltration. The final body weight of the rats in the low-dose

medium-dose

and high-dose dexmedetomidine group was higher than that in the model group

the intestinal wall erosion and bleeding were reduced to varying degrees

the colon tissue structure was relatively complete compared with the model group

and the degree of inflammatory cell infiltration decreased. Compared with the normal group

the levels of serum TNF-α and IL-1β and the expression of RhoA and ROCK1 proteins of colon cancer tissue in the model group increased significantly（P<0.05）. Compared with the model group

the levels of serum TNF-α and IL-1β

and the expression of RhoA and ROCK1 proteins of colon cancer tissue in the low-dose

medium-dose

and high-dose dexmedetomidine group decreased significantly

with statistically significant differences（P<0.05）. CONCLUSIONS: Dexmedetomidine has a certain therapeutic effect on colon cancer rats

which may be related to its inhibition of RhoA/ROCK1 pathway.

关键词

右美托咪定结肠癌大鼠Ras同源基因家族成员ARho相关卷曲螺旋蛋白激酶1

Keywords

DexmedetomidineColon cancer ratsRas homolog gene family member ARho-associated coiled-coil containing protein kinase 1

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Continuous Intravenous Infusion of Dexmedetomidine Combined with Oxycodone on Inflammatory Response and Immune Function in Patients with Breast Cancer During General Anesthesia

Protective Effects of Dexmedetomidine Combined with Sufentanil on Cerebral Oxygen Metabolism and Liver Function in Elderly Patients During Recovery from General Anesthesia

Effects of Different Loading Doses of Dexmedetomidine on Postoperative Recovery of Intestinal Function in Patients with Gastrointestinal Tumor

Application Effect of Different Doses of Dexmedetomidine Combined with Ropivacaine in Knee Arthroplasty in Elderly Patients

Clinical Application of Dexmedetomidine Combined with EEG Bimodal Index Monitoring on Awake Extubation Under General Anesthesia in Children

Related Author

LIU Xiaomei

NING Lijuan

LYU Hao

XIAO Guofeng

LIU Hongman

ZHANG Xiaoling

ZHANG Zhezhe

QI Chao

Related Institution

Dept.of Anesthesiology,Sixth Medical Center of Chinese PLA General Hospital

Dept.of Anesthesiology, the 6th Medical Center of the PLA General Hospital

Dept.of Anesthesiology,Fuyang People’s Hospital

Dept.of Pediatric Orthopedic,the Third Hospital of Shijiazhuang

Dept.of Anesthesiology,the Third Hospital of Shijiazhuang

⁰